Patents by Inventor Argaw Kidane

Argaw Kidane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating seizures using modified release formulations of oxcarbazepine
    Patent number: 7910131
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 22, 2011
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Pharmaceutical Composition Comprising Trospium Chloride for Once-A-Day Administration
    Publication number: 20100222375
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR THE ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221352
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221355
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw KIDANE, Henry H. FLANNER, Padmanabh BHATT, Arash RAOUFINIA
  • PHARMACEUTICAL COMPOSITION FOR ONCE A DAY ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221356
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221354
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Pharmaceutical Composition For Once-A-Day Administration of Trospium Chloride
    Publication number: 20100221353
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Trospium chloride treatment method
    Patent number: 7781449
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Patent number: 7781448
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Patent number: 7763635
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 27, 2010
    Assignee: Supermus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Method of treating bladder dysfunction with once-a-day trospium salt formulation
    Patent number: 7759359
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 20, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Modified-release preparations containing oxcarbazepine and derivatives thereof
    Patent number: 7722898
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: May 25, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Osmotic delivery of therapeutic compounds by solubility enhancement
    Patent number: 7611728
    Abstract: The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: November 3, 2009
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Shimul K. Ray, Padmanabh P. Bhatt, Jones W. Bryan, Jr.
  • ENHANCED FORMULATIONS OF LAMOTRIGINE
    Publication number: 20090022789
    Abstract: A once-a-day, extended-release formulation of lamotrigine, exhibiting a significantly similar release rate throughout the GI tract irrespective of the pH of the environment, is provided. The formulation comprises lamotrigine, an organic acid, a release enhancing polymer and a release controlling polymer. The use of the formulation for the treatment of the neurological disorders is also disclosed.
    Type: Application
    Filed: July 18, 2007
    Publication date: January 22, 2009
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Kevin Edwards, Padmanabh P. Bhatt
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Publication number: 20090005360
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: August 27, 2008
    Publication date: January 1, 2009
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Publication number: 20090004263
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: August 27, 2008
    Publication date: January 1, 2009
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Once daily dosage forms of trospium
    Publication number: 20080207663
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Publication number: 20080207661
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Publication number: 20080207664
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Publication number: 20080207662
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia